

Paris 8èmes journées de la SFSPM et 4èmes de la SIS

8èmes journées de la Société Française
de Sénologie et de Pathologie Mammaire
couplé au 4ème congrès de la
Société Internationale de Sénologie,
septembre 1986
Masson, Paris

1. THEME I – DIAGNOSTIC ET TERMINOLOGIE DES MALADIES DU SEIN TOPIC I – DIAGNOSIS AND TERMINOLOGY OF BREAST DISEASES

Mardi 2 septembre – Tuesday September 2	1
Prebiopsy localization of non palpable breast lesions, S. FEIG, G. SCHWARTZ	
Aspect mammographique du carcinoma lobulaire infiltrant, M. LE GAL	6
Ductal carcinoma in situ and lobular carcinoma in situ : definition and diagnosis, P.P. ROSEN	7
Breast imaging : magnification mammography, diaphanography, CT scanning, heavy-particle mammography, and MR imaging	10
Sur et sous-estimation du diagnostic de malignité en histopathologie mammaire, M. TROJANI, I. DE MASCAREL, J.M. COINDRE	15
Cancers infracliniques du sein. A propos de 83 cas, J.M. TUBIANA, B. DUPERNAY, I. MOROT, L. THONEL, Ch. DRUMLEWICZ	19
Mercercredi 3 septembre – Wednesday September 3	
La mammographie digitale, M. COLLARD (texte non parvenu – Not received)	
Three dimensional reconstruction in mammography, W. GORDENNE, F. MALCHAIR, J. DESTINE	23
Microcalcifications : differential diagnosis, M. LANVI	25
Radial scar. Definition, Relationship to breast carcinoma, F. LINELL, O. LJUNGBERG	26
Breast ultrasound examination, E.A. SICKLES	28
Galactography and pneumocystography, L. TABAR	30
MRI in breast tumors, D. VANAL, J. MASSELOT, G. CONTESSO, D. CASTAIGNE, D. SARRAZIN	31

2. THEME II – HORMONES ET MALADIES DU SEIN TOPIC II – HORMONES AND BREAST DISEASES

Mardi 2 septembre – Tuesday September 2	32
Mécanisme d'action des anti-oestrogènes dans les cancers du sein, J.L. BORGNA, H. ROCHEFORT	
Prolactin receptors in normal and neoplastic mammary cells, J. DJANE, P.A. KELLY, J.P. PEYRAT, I. DUSANTER-FOURT, M. KATDH	37

Estrogenic regulation of human breast cancer, M.E. LIPPMAN, R.B. DICKSON, E.P. GELMANN, A. KASID, S. BATES, C. KNABBE, S.M. SWAIN, M. McMANAWAY, G. WILDING, N. DAVIDSON, K. HUFF, D. BRONZERT	41
Progrès récents dans l'étude de l'action des hormones stéroïdes, E. MILGROM, H. LOOSFELT, M. ATGER, F. LOGEAT, M. APPLANAT, A. BAILLY (texte non parvenu) – Not received)	
Oestrogen production and metabolism by human breast tumours, W.R. MILLER	44
Intérêt clinique de la mesure des récepteurs des stéroïdes : le point de 1986, S. SACZ	49
Mercredi 3 septembre – Wednesday September 3	235
Immunocytochemical localization of progesterone receptor in human breast cancers, M. PERROY-APPLANAT, M.T. GROUYER-PICARD, F. LORENZO, A. JOLIVET, M.T. VU AHI, C. PALLUD, F. SPYRATOS, E. MILGROM	
Immunochemical analyses of steroid receptors in breast cancer, G.L. GREENE, M.F. PRESS	55
Interaction des récepteurs hormonaux avec le DNA, B. GRONER (texte non parvenu – Not received)	
Epithelial-stromal interactions in mammary gland development, K. KRATOCHWIL	59
Monoclonal antibodies against progesterone receptor, F. LOGFAT, M. PERROT-APPLANAT, H. LOOSFELT, A. JOLIVET, F. LORENZO, E. MILGROM	61
Early studies of LH-RH action in breast cancer, R.I. NICHOLSON, K.J. WALKER, A. TURKES, J. DYAS, P.N. PLOWMANN, M. WILLIAMS, R.W. BLAMEY	62
Autocrine regulation of breast cancer cell growth by the estrogen-induced 52K protein, F. VIGNON, F. CAPONY, M. CHAMBON, G. FREISS, M. GARCIA, M. MORISSET, H. ROCHEFORT	67
3. THEME III – EPIDEMOLOGIE ET DEPISTAGE	
TOPIC III – EPIDEMIOLOGY AND SCREENING	
Mercredi 3 septembre – Wednesday September 3	70
Screening tests for breast cancer, J. CHAMBERLAIN, R. ELLMAN	
Nutrition et cancer du sein, F. DE WAARD	72
Benefit and risk considerations in screening, S. FEIG	76
Oral contraceptives and breast cancer : a selective review of literature, A. KALACHE, M. CALEFFI	81
Exogenous estrogens and breast cancer, J. KELSEY	88
Contraceptifs oraux et cancer du sein : résultats d'une étude cas-témoins française, M.G. LE, A. BACHELOT	90
Jeudi 4 septembre – Thursday September 4	91
Diet in the epidemiology of breast cancer, S. GRAHAM	
Non-dietary risk factors for breast cancer, J. KELSEY	96
Genetics and breast cancer, H. LYNCH, J. MARCUS, J. LYNCH, P. SHEA, G. SCHUELKE, R. CALLAHAN, A. THOR, J. SCHLOM	102

Conclusions of the UICC project on screening for breast cancer, A.B. MILLER, N.E. DAY, C.J. BAINES, J. CHAMBERLAIN, M. HAKAMA, P. PROROK	236
Descriptive epidemiology of breast cancer, C.S. MUIR, A.S. DONN, P. BOYLE	102
The results of periodic one-view mammography screening in a randomised controlled trial in Sweden. Part I, I.G. FAGERBERG, L. BALDETORP, O.GRÖNTOFT, J. MANSON	104
The results of periodic one-view mammography screening in a randomized controlled Trial in Sweden part II, L. TABAR, A. GAD, L. HOLMBERG, U. LJUNGQUIST	105
4. THEME IV – MASTOPATHIES BENIGENES ET ETATS PRECANCEREUX	
TOPIC IV – BENIGN AND PREMALIGNANT DISEASE OF THE BREAST	
Mercredi 3 septembre – Wednesday September 3	106
Injection percutanée d'un produit de contraste et étude de la vitesse de croissance des fibroadénomes mammaires, C. COLIN	
Définition et classification, anatomo-pathologique des mastopathies bénignes, G. CONTESSO, G. BERTIN, M.J. LACOMBE	110
Rôle du chirurgien dans le diagnostic et le traitement des tumeurs bénignes, J.C. DURAND	117
Triple diagnosis : clinical, radiological and cytological, G. KREUZER, Th. PARADOWSKI	120
Estrogen and progesterone receptors in benign breast tumors and lesions : relationship with histological and cytological feature, M.J. LACOMBE, C. GIANI, E. D'AMORE, J.C. DELARUE, H. MOURIESSE, F. MAY-LEVIN, H. SANCHO-GARNIER, G. CONTESSO	123
Hormonal therapy of benign breast disease, P. MAUVAIS-JARVIS, R. SITRUK-WARE	128
Mastopathies bénignes et risque de cancer du sein chez la femme. Etude coopérativerétrospective des Centres de Lutte contre le Cancer. Rapporteur : C. PALLUD	133
Jeudi 4 septembre – Thursday September 4	136
Estradiol and progesterone interaction on normal and pathological breast tissue, F.KUTTEN, C. MALET, A. GOMPEL, P. SPRITZER, S. FOURNIER, G. CHOMETTE, P. MAUVAIS-JARVIS	
Histogenetic theories of breast carcinoma, F. LINELL, O. LIUMBERG	141
New morphological methods in the study of benign mastopathies, A. LLOMBART-BOSCH, F. VERA-SEMPERE, M. GONZALES-DEUFSA, C. CALABUIG, M. PEREZ-BACETTE, A. PEYDRO-OLAYA	144
Flow cytometry of breast cancer, M.R. MELAMED	147
The proliferative breast disease concept and risk factors for carcinoma, L. OZZELIO	148
New entities with potential precancerous significance, P.P. ROSEN	150
5. THEME V – BIOLOGIE NON HORMONALE DES MALADIES DU SEIN	
TOPIC V – NON HORMONAL BIOLOGY OF BREAST DISEASES	
Mardi 2 septembre – Tuesday September 2	154
Human endogenous retroviral genes and proto-oncogenes in breast carcinomas, R. CALLAHAN, I. ALI, M.H. CHAMPENE, C. ESCOT, J. GEST, R. LIDEFREAU, J. SCHLOM, C. THEILLET	

Milk proteins : differentiation markers in breast pathology, J. COLLETTE, V. LE DOUSSAL, J.R. VAN CAUWENBERGE, F. SPYRATOS, J. HUSYIN, P. FRANCHIMONT	159
GCDFP-16 – a tumor marker of breast carcinoma : serological and immunohistological findings, D. HAAGENSEN, G. MAZDUJIAN, W. DILLEY, S. WELLS	164
Human monoclonal antibodies directed against viral antigens associated with human breast carcinoma, I. KEYDAR, N.I. TSARFATI, E. SAHAR, S. CHAITCIK, Y. SHOENFELD	169
Potential clinical utility of radiolabelled monoclonal antibodies in the management of human breast cancer, F. MORNEX, D. COLCHER, M.O. WEEKS, J. SCHLOM	243
Molecular and immunological analysis of mucin-like molecules from human breast epithelial-cells, J. TAYLOR-PAPADIMITRIOU, J. BURCHELL, S. GENDLER, A. GRIFFITHS	170
Jeudi 4 septembre – Thursday September 4	172
Oncogenes and human Malignancies, S.A. AARONSON	
Le récepteur humain des oestrogènes, P. CHAMBON (texte non parvenu – Not received)	
Invasivité et métastases des cancers du sein, P.M. MARTIN, F. KOPP, J.C. LISSITZKY	173
Host defense mechanisms in breast patients, M. MICKSCHE, R. KOLB, R. JAKESZ, H. RAINER, Ch. DITTRICH, K. MOSER, P. SAGASTER, A. UCHIDA, E. YANAGAWA	248
Biological markers of the human breast and its disorders, A.M. NEVILLE	178
Regulation of normal growth and nooplasia by the EGF-receptor, J. SCHLESSINGER	190
Translation of tumor-associated and proto-oncogene products in human mammary carcinoma cell population, J. SCHLOM, A. THOR, N. OHUCHI, P. HAND, D. WUNDERLICH, R. MURARO, M. WECKES, D. COLCHER, D. PAGE, C. SZPAK, W. JOHNSTON	181
6. theme vi – traitements du cancer du sein topic vi – treatments of breast cancers	
Mardi 2 septembre – Thesday September 2	186
Adjuvant systemic trials : Tamoxifen postmenoposal cytotoxic, premenopausal ? C.HILL, R. PETO	
Neoadjuvant chemotherapy in the conservative management of breast cancers. Study On 205 patients, CI JACQUILLAT, M. WEILI, G. AUCLERC, M. SELLAMI, M.F.AUCLERC, D.KHAYAT, R. PETO	187
Immunologic monitoring and immunotherapeutic reagents : new approaches to the management of breast cancer, D.M. LOPEZ	195
Terminology and pathology of inflammatory breast cancer, P.P. ROSEN	200
Les protocoles de chimiothérapie dans les cancer inflammatoires, J. ROUESSE, T. LE CHEVALIER, D. SARRAZIN	202
Clinical significance and staging of non-palpable breast cancer, F.G. SCHWARTZ, S.A. FEIG, A.L. ROSENBERG, A.S. PATCHEFKY	210
Long-term results of quadrantectomy. The Milan trial, U. VERONESI, M. DEL VECCHIO, A. LUINI, R. ZUCALI	213

Jeudi 4 septembre – Thursday September 4	215
Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer, G. BONADONNA	
The state of pre-operative radiotherapy in breast cancer, H. HOST, J. HOIE, O.MONGE, H. MELSOM, O. KAALHUS	216
Intraductal breast carcinoma : definition, diagnosis, and prognosis, J. JACQUEMIER, D.HANS, P. MEYNARD, Y. AYME, J. HASSOUN	219
Radical or conservative surgical treatment of intraductal carcinoma, F. KRAUER, P. SCHÄFER, D. OBRADOVIC	225
The part of reconstructive surgery in the management of the intraductal carcinomas, M.LEJOUR, R. DEBAEMAECKER, M. JABRI, A. DE MEY, H. EDER, J. DUCHATEAU, P. GELINCK, A.DECLETY	226
Adjuvant hormone therapy in operable breast cancer, T.J. POWLES (texte non parvenu – Not received)	
7. SYMPOSIUM SATELLITE HORMONOTHERAPIE DES CANCERS GYNECOLOGIQUES SATELLITE SYMPOSIUM HORMONOTHERAPY IN GYNECOLOGIC CANCERS Laboratoires Upjohn – France	
Lundi 1er septembre – Monday September 1	229
Intérêt d'une présentation de l'acétate de médroxyprogestérone en comprimés de 200mg. Considérations pharmacocinétiques et cliniques, P. POUILLART, J. PALANGIE, T. DORVAL, M. JOUVE, E. GARCIA-GIRALT	
The bioavailability of the tablet formulation of medroxyprogesterone acetate, provera 200mg, compared with the old tablet formulation, Provera 100mg in healthy malevolunteers, A. BYE	230
Treatment of advanced breast cancer with medroxyprogesterone acetate : a randomized ovaluation of the dose-response relationship to two-dose levels, C. ROSC, C. KAMBY,E.ENGELSMAN, M. NOOT, H.T. MOURIDSEN, R. SYLVESTER, N. ROTMENSZ..	232
Place de la MPA dans les traitements adjuvants des cancers du sein – Aspects prospectifs, A. BREMOND	233
Hormonothérapie adjuvante par acétate de médroxyprogestérone des carcinomes de l'endomètre, M. BOLA	234